Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation | |
---|---|---|
D058186 | Acute Kidney Injury NIH | 0.45 |
D014947 | Wounds and Injuries NIH | 0.41 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
ACE-ID- 201 will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
Description: Treatment failure rate, where treatment failure is defined as use of assisted ventilation or death.
Measure: Treatment failure rate Time: Approximately 30 daysDescription: Peak Plasma Concentration (Cmax)
Measure: Pharmacokinetics of acalabrutinib and its active metabolite ACP-5862 (Cmax) Time: Approximately 30 daysDescription: Time to Maximum Concentration (Tmax)
Measure: Pharmacokinetics of acalabrutinib and its active metabolite ACP-5862 (Tmax) Time: Approximately 30 daysDescription: Area under the plasma concentration versus time curve (AUC)
Measure: Pharmacokinetics of acalabrutinib and its active metabolite ACP-5862 (AUC) Time: Approximately 30 days